DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability. The company has obtained U.S.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

Frontiers in Cardiovascular Medicine

JANUARY 16, 2024

Introduction Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n  = 27) had persistent atrial fibrillation.

Atrial Fibrillation 64

Atrial Fibrillation Cardiomyopathy Ablation Heart Failure 64

DAIC

FEBRUARY 2, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.

Ablation 105

Ablation Atrial Fibrillation AFIB Heart Rhythm 105

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. Data were collected from the MPH AF Ablation Registry with the approval of the institutional research board. 11.4), and left atrial width as measured on CT in the upper quartile ( p  = 0.04, HR: 2.5,

Ablation 64

Ablation Atrial Fibrillation BMI Arrhythmia 64

Dr. S. Venkatesan MD

APRIL 28, 2024

When atrial fibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.

Atrial Fibrillation 75

Atrial Fibrillation Bicuspid/Mitral Pulmonary Ablation 75

Open Heart

JANUARY 18, 2024

Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.

Atrial Fibrillation 69

Atrial Fibrillation Ablation Pulmonary Arrhythmia 69

Frontiers in Cardiovascular Medicine

DECEMBER 14, 2023

Typical atrial flutter commonly occurs in patients with atrial fibrillation (AF). Limited information exists regarding the effects of concurrent atrial flutter on the long-term outcomes of rhythm control. The data were obtained from a multicenter registry of cryoballoon ablation for AF ( n  = 2,689).

Atrial Flutter 64

Atrial Flutter Atrial Fibrillation Ablation Arrhythmia 64

Frontiers in Cardiovascular Medicine

DECEMBER 18, 2023

Background Cryoballoon ablation (CBA) and laser balloon ablation (LBA) are two innovative ways for the treatment of atrial fibrillation (AF). This study aimed to evaluate the efficacy and safety of cryoballoon ablation and laser balloon ablation in patients with AF.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Innovation Arrhythmia 64

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1%

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

HeartRhythm

DECEMBER 16, 2024

A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1 A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Cardiomyopathy Risk Factors 40

Open Heart

DECEMBER 18, 2024

Introduction Pulsed-field ablation (PFA) is a novel modality for pulmonary vein isolation in patients with atrial fibrillation (AF). first-time AF ablation. first-time AF ablation. In first-time ablation cases, acute isolation of all pulmonary veins was achieved in 99.5% The patients were 32.1% of patients.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Pulmonary Arrhythmia 52

Journal of Cardiovascular Electrophysiology

NOVEMBER 3, 2024

Abstract Background and Aims Atrial fibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable treatment option for selected patients. However, its safety profile in liver cirrhosis (LC) populations remains underexplored.

Atrial Fibrillation 56

Atrial Fibrillation Ablation Inpatient Hospital 56

Circulation

NOVEMBER 29, 2023

Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.

Atrial Fibrillation 76

Atrial Fibrillation Risk Factors Ablation Arrhythmia 76

DAIC

JANUARY 18, 2024

milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).

Heart Rhythm 105

Heart Rhythm Ablation AFIB Chest Pain 105

HeartRhythm

DECEMBER 11, 2024

Asthma is a known risk factor for atrial fibrillation (AF), the most common sustained arrhythmia. While radiofrequency catheter ablation is effective in treating AF, the impact of asthma and its severity on ablation outcomes has not been previously explored.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Risk Factors Arrhythmia 40

HeartRhythm

JANUARY 25, 2024

Early recurrence of atrial arrhythmia (ERA) is commonly seen following catheter ablation of atrial fibrillation (AF), with reported incidences of up to 61% in the first three months.1

Atrial Fibrillation 45

Atrial Fibrillation Ablation Physiology Arrhythmia 45

HeartRhythm

DECEMBER 29, 2024

Early recurrence of atrial tachyarrhythmia (ERAT) is common following catheter ablation of atrial fibrillation (AF). The specific clinical and arrhythmia characteristics of ERAT influencing late recurrence risk in persistent AF is unclear.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia 40

HeartRhythm

SEPTEMBER 15, 2024

Acutely effective repeat radiofrequency catheter ablation (RFCA) after previous atrial fibrillation ablation depends on several parameters including local impedance (LI), contact force (CF) and power.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia 40

HeartRhythm

SEPTEMBER 23, 2024

Atrial fibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Rhythm Electrophysiology 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 7, 2024

Catheter ablation of atrial fibrillation in infiltrative cardiomyopathies ABSTRACT Atrial and ventricular arrhythmias are common in patients with Infiltrative heart diseases. AF is the most common arrhythmia identified in patients with amyloidosis due to cellular infiltration and atrial dilation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Cardiomyopathy Arrhythmia 40

HeartRhythm

OCTOBER 17, 2024

Atrial fibrillation (AF) and premature ventricular complexes (PVCs) are common arrhythmias associated with significant morbidity and mortality.1,2 3 Catheter ablation is recommended for AF and PVCs in symptomatic, drug-refractory patients, but evidence for combined ablation is lacking.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Hospital 40

Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

Despite the relative efficacy of ablation, the risk of AF recurrence is substantial, particularly in patients with persistent AF (perAF). At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation.

Pulmonary 64

Pulmonary Ablation Atrial Fibrillation Electrophysiology 64

HeartRhythm

APRIL 30, 2024

There is a limited knowledge on atrial arrhythmias recurring after complex left atrial (LA) pulsed field ablation (PFA) for longstanding persistent atrial fibrillation (LSPAF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulmonary vein isolation (PVI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with those with paroxysmal AF. to 3.4%]; hazard ratio, 0.66 [95% CI, 0.460.94]). to 3.4%]; hazard ratio, 0.66 [95% CI, 0.460.94]).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) catheter ablation trials report arrhythmia-free survival using different post-ablation rhythm monitoring protocols, resulting in difficulties in the interpretation of the recurrence rates and comparison of ablation strategies and technologies.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Arrhythmia 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. One-year freedom from atrial arrhythmia was 80.2% (95% CI, 69.7%87.4%) One-year freedom from atrial arrhythmia was 80.2% (95% CI, 69.7%87.4%)

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Outcomes 40

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Catheter ablation (CA) has emerged as an important modality for managing AF, improving quality of life, and potentially reversing cardiac dysfunction.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Quality of Life Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Animal studies suggest that catheter ablation-associated parasympathetic and sympathetic denervation could result in increased ventricular arrhythmias (VA). The impact of catheter ablation of atrial fibrillation on VA burden in humans has not been assessed.

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Ablation Pulmonary 40

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF), a common cardiac arrhythmia, presents unique management challenges, particularly in patients with varying degrees of frailty. This study aims to elucidate the impact of frailty on readmission rates and the utilization of ablation therapy in AF patients.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Persistent atrial fibrillation (AF) is commonly treated with ablation, yet the optimal strategy for ablating this arrhythmia remains unclear.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Outcomes 40

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) is the most common cardiac arrhythmia with increasing prevalence globally. Catheter ablation is well-established treatment for prevention of AF recurrences and decreasing AF symptoms.

Atrial Fibrillation 40

Atrial Fibrillation Atrial Flutter Ablation Arrhythmia 40

American College of Cardiology

DECEMBER 2, 2024

When pulsed field ablation (PFA) achieved European CE mark approval in January 2021 and U. Food and Drug Administration (FDA) approval in December 2023, it opened up the proverbial Pandora's Box for treating not only atrial fibrillation (AFib), but also ventricular arrhythmias.

Arrhythmia 40

Arrhythmia Ablation Atrial Fibrillation AFIB 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 26, 2024

ABSTRACT Introduction Atrial fibrillation (AF) can cause or aggravate heart failure (HF). Catheter ablation (CA) is an effective treatment for AF. This study focused on the feasibility and outcomes of emergent AF ablation performed during hospitalization for acute HF. Arrhythmia recurrence was the primary endpoint.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Hospital 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 11, 2024

This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% identification rate of PLSVC-related triggers and an 85% success rate in acute isolation or targeted ablation. The recurrence rate of arrhythmia postablation was 46.7% However, a 46.7%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Pulmonary 40

HeartRhythm

APRIL 30, 2024

Colchicine (C) is used to reduce inflammation and atrial arrhythmia recurrence after atrial fibrillation (AF) ablation, but prior studies have yielded mixed results.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia 40

Frontiers in Cardiovascular Medicine

DECEMBER 15, 2023

Background Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of stroke and other cardiovascular complications. Oral anticoagulants (OACs) are effective in reducing this risk. To investigate the knowledge, attitude and practice (KAP) toward OACs among patients with AF.

Atrial Fibrillation 64

Atrial Fibrillation Education Ablation Arrhythmia 64

Journal of Cardiovascular Electrophysiology

DECEMBER 23, 2024

ABSTRACT Introduction Catheter ablation of persistent atrial fibrillation yields sub-optimal success rates partly due to the considerable heterogeneity within the patient population. Methods We studied all patients who underwent catheter ablation of persistent atrial fibrillation in the DECAAF II trial.

Atrial Fibrillation 40

Atrial Fibrillation BMI Ablation Arrhythmia 40